Transcriptome Landscape of Cancer‐Associated Fibroblasts in Human PDAC
Cancer-associated fibroblasts (CAFs) play a crucial role in the progression of pancreatic ductal adenocarcinoma (PDAC). Here, integrated single-cell RNA sequencing analysis is utilized to comprehensively map CAFs in the human PDAC tumor microenvironment (TME). Normal fibroblasts (NFs) and nine distinct CAF subtypes are identified including newly identified CAF subtypes, CDCP1<sup>+</sup>FTL<sup>+</sup> CAFs, transitional CAFs (tCAFs), interferon simulated genes (ISG)<sup>+</sup> myofibroblastic CAFs (myCAFs), and proliferative CAFs (pCAFs). CDCP1<sup>+</sup>FTL<sup>+</sup> CAFs, pCAFs, and ISG<sup>+</sup> myCAFs are associated with unfavorable clinical outcomes. CDCP1<sup>+</sup>FTL<sup>+</sup> CAFs exhibit enhanced glycolysis and iron metabolism, resisting ferroptosis. The antigen-presenting CAFs (apCAFs) show high heterogeneity, consisting of multiple subtypes expressing distinct immune cell signatures. The CAF subtypes display differentiation plasticity, transitioning from early normal-like CAFs (nCAFs) to inflammatory CAFs (iCAFs) and myCAFs, ultimately leading to more invasive pCAFs. AP-1 family members FOS and JUN regulate the malignant phenotype conversion of NFs to nCAFs, while transforming growth factor-β (TGFβ) and interferon-γ (IFNγ) signals trigger the interconversion between classic myCAFs and iCAFs, respectively. A close interaction between CAFs and myeloid cells (especially neutrophils) is further observed in PDAC-TME, mainly mediated by CXCR4-CXCL12 chemotaxis. This work depicts a detailed CAF map and its dynamic interconvertible shift, providing important insights for combined targeted CAFs therapy.
Authors
- Mingzhu Huang (ORCID: https://orcid.org/0000-0002-0437-5737)
- Cheng Zhou (ORCID: https://orcid.org/0000-0002-4091-4777)
- Qingjian Chen (ORCID: https://orcid.org/0000-0003-0628-3198)
- Yuxuan Zheng (ORCID: https://orcid.org/0000-0002-2109-331X)
- Rujiao Liu (ORCID: https://orcid.org/0000-0002-6803-0594)
- Mengyu Tao (ORCID: https://orcid.org/0000-0002-1500-304X)
- Shuguang Tan (ORCID: https://orcid.org/0000-0002-2599-4959)
- Chenchen Wang (ORCID: https://orcid.org/0009-0004-2630-4149)
- Hongxia Wang (ORCID: https://orcid.org/0000-0003-3481-6940)
- Jianhua Chen (ORCID: https://orcid.org/0009-0002-2575-7803)
- Wenting Liu (ORCID: https://orcid.org/0000-0003-1461-3740)
- Bo Yu (ORCID: https://orcid.org/0009-0008-0286-7480)
- Zhe Zhang (ORCID: https://orcid.org/0000-0001-6711-2259)
- Haoyu Sun (ORCID: https://orcid.org/0000-0002-7506-8806)
- Jianling Zou
- Zhiyu Chen (ORCID: https://orcid.org/0009-0002-4679-0880)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Nanfang Hospital (CN)
- Shanghai First People's Hospital (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Advanced Science
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1002/advs.202415196
- Citations
- 16
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 14.98
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China